Download MendeleyIn vitro generated antibodies guide thermostable ADDomer nanoparticle design for nasal vaccination and passive immunization against SARS-CoV-2.
Buzas, D., Bunzel, A.H., Staufer, O., Milodowski, E.J., Edmunds, G.L., Bufton, J.C., Vidana Mateo, B.V., Yadav, S.K.N., Gupta, K., Fletcher, C., Williamson, M.K., Harrison, A., Borucu, U., Capin, J., Francis, O., Balchin, G., Hall, S., Vega, M.V., Durbesson, F., Lingappa, S., Vincentelli, R., Roe, J., Wooldridge, L., Burt, R., Anderson, R.J.L., Mulholland, A.J., Hare, J., Bailey, M., Davidson, A.D., Finn, A., Morgan, D., Mann, J., Spatz, J., Garzoni, F., Schaffitzel, C., Berger, I.(2023) Antib Ther 6: 277-297
- PubMed: 38075238
- DOI: https://doi.org/10.1093/abt/tbad024
- Primary Citation of Related Structures:
8C9N - PubMed Abstract:
Due to COVID-19, pandemic preparedness emerges as a key imperative, necessitating new approaches to accelerate development of reagents against infectious pathogens. Here, we developed an integrated approach combining synthetic, computational and structural methods with in vitro antibody selection and in vivo immunization to design, produce and validate nature-inspired nanoparticle-based reagents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our approach resulted in two innovations: (i) a thermostable nasal vaccine called ADDoCoV, displaying multiple copies of a SARS-CoV-2 receptor binding motif derived epitope and (ii) a multivalent nanoparticle superbinder, called Gigabody, against SARS-CoV-2 including immune-evasive variants of concern (VOCs). In vitro generated neutralizing nanobodies and electron cryo-microscopy established authenticity and accessibility of epitopes displayed by ADDoCoV. Gigabody comprising multimerized nanobodies prevented SARS-CoV-2 virion attachment with picomolar EC 50 . Vaccinating mice resulted in antibodies cross-reacting with VOCs including Delta and Omicron. Our study elucidates Adenovirus-derived dodecamer (ADDomer)-based nanoparticles for use in active and passive immunization and provides a blueprint for crafting reagents to combat respiratory viral infections.
Organizational Affiliation:
Max Planck Bristol Centre for Minimal Biology, University of Bristol, Bristol BS8 1TS, UK.
